Fig. 5: Effect of sAPPα expression on markers of neuroinflammation. | Gene Therapy

Fig. 5: Effect of sAPPα expression on markers of neuroinflammation.

From: Virus-mediated gene transfer of soluble amyloid precursor protein-alpha via systemic injection in a mouse model of Alzheimer’s disease

Fig. 5: Effect of sAPPα expression on markers of neuroinflammation.

A Representative GFAP expression in the hippocampus and overlying cerebral cortex. B Representative Iba-1 expression is covered by GFAP labelling in the hippocampus and cortex. There was a significant increase in the spread of GFAP labelling in Tg mice compared to WT mice for both regions of interest, but this was not affected by hsAPPα treatment. Median (IQR): C WT+Control: 4.89 (2.35), n = 6; Tg+Control: 10.14 (1.79), n = 5; Tg+hsAPPα: 8.57 (2.17), n = 3. D WT+Control: 0.064 (0.058), n = 6; Tg+Control: 2.58 (0.67), n = 5; Tg+hsAPPα: 2.03 (0.65), n = 3. E, F Bar graphs showing the percentage area covered by Iba-1 labelling in the hippocampus and cortex. There was an increase in Iba-1 labelling in Tg mice compared to WT mice in both regions of interest, albeit not significantly in the cortex. The hsAPPα treatment prevented this increase, in that the Tg+hsAPPα group was not significantly different from the WT+control group. Median (IQR): E: WT+Control: 2.58 (1.95), n = 5; Tg+Control: 5.25 (1.50), n = 5; Tg+hsAPPα: 2.57 (1.43), n = 3. F: WT+Control: 5.37 (1.20), n = 5; Tg+Control: 10.57 (1.20), n = 5; Tg+hsAPPα: 5.64 (1.55), n = 3. * p \( < \,\)0.05, ** p \( < \,\)0.01; Mann–Whitney tests.

Back to article page